COMMUNIQUÉS West-GlobeNewswire

BioVie Inc. Announces Closing of Public Offering

25/09/2024 - 22:05

CARSON CITY, Nev., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

25/09/2024 - 22:05

PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the [...]

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

25/09/2024 - 22:05

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data [...]

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

25/09/2024 - 22:05

Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global [...]

ImPact Biotech to Present at Oppenheimer Private Life Sciences Company Showcase

25/09/2024 - 22:01

TEL AVIV, Israel, Sept. 25, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid [...]

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

25/09/2024 - 22:01

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax [...]

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

25/09/2024 - 22:00

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses [...]

Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024

25/09/2024 - 22:00

Le recrutement dans l'étude clinique NATiV3 progresse, avec plus de 85 % du nombre cible de patients randomisés dans la cohorte principale et d'une puissance statistique de l'étude qui devrait être supérieure à 95 % [...]

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

25/09/2024 - 22:00

NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic [...]

HOOPP President & CEO Jeff Wendling announces retirement

25/09/2024 - 21:00

TORONTO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Jeff Wendling, President & CEO of the Healthcare of Ontario Pension Plan (HOOPP), announced today that he will be retiring in 2025 after more than a quarter of a century [...]

Nextech Launches Expanded Payments Functionality

25/09/2024 - 20:30

New Features to Enhance Patient Experience and Increase Speed to Revenue TAMPA, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty physician practices, [...]

Multiple Myeloma Research Foundation (MMRF) Presents New Data from Multiple Myeloma Research Programs at the 21st International Myeloma Society Annual Meeting

25/09/2024 - 18:00

Findings reinforce the value of the MMRF’s integrated clinical and translational research expertise to provide a deeper understanding of multiple myeloma and improve how the disease is treated The MMRF CoMMpass SM Study [...]

SLEEVER® and CARBIOS globally launch world’s first Home Compost biodegradable tamper evident seal: SEELCAP® ONEGO

25/09/2024 - 18:00

The SEELCAP® ONEGO innovation is the fruit of a long-term partnership between SLEEVER® and CARBIOS that combines their expertise to produce more environmentally friendly packaging security SEELCAP® ONEGO will be [...]

SLEEVER® et CARBIOS lancent le premier concept de témoin d’effraction Home Compost biodégradable sur le marché mondial : SEELCAP® ONEGO

25/09/2024 - 18:00

L’innovation SEELCAP® ONEGO est le fruit du partenariat long terme entre SLEEVER® et CARBIOS qui conjuguent leurs expertises pour la sécurisation d’emballages plus respectueux de l’environnement SEELCAP® ONEGO sera [...]

GUERBET : Résultats semestriels 2024.

25/09/2024 - 17:45

Résultats semestriels 2024 Activité très dynamique Chiffre d’affaires du 1 er semestre : 419,2 M€, en hausse de 11,8% à TCC 1 Une trajectoire portée par l’ensemble des activités et des zones géographiques Solide [...]

GUERBET : H1 2024 results.

25/09/2024 - 17:45

H1 2024 results Very dynamic business activity H1 revenue: €419.2m, up 11.8% at CER 1 A trajectory driven by all activities and geographical areas Solid increase in profitability The restated EBITDA margin 2 was 15.4%, [...]

PHAXIAM : RAPPORT FINANCIER SEMESTRIEL

25/09/2024 - 17:45

Rapport Financier Semestriel 30 Juin 2024 PHAXIAM Pièce jointe PHXM_RFS_2024

PHAXIAM Provides Business and Financial Update For the First Half of 2024

25/09/2024 - 17:45

Continuous commitment to create a global leader in phage therapies to treat severe and resistant bacterial infections Ambitious development strategy on track with clear objectives set for the Prosthetic Joint Infections [...]

PHAXIAM fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024

25/09/2024 - 17:45

Engagement continu pour créer un leader mondial de la phagothérapie pour traiter des infections bactériennes sévères et résistantes Une stratégie de développement ambitieuse en ligne avec les objectifs fixés pour le [...]